Sanofi's experimental eczema drug amlitelimab falls short of expectations, raising concerns about the company's ability to replace Dupixent's revenue after patent expiry.
Sanofi's experimental eczema drug amlitelimab falls short of expectations, raising concerns about the company's ability to replace Dupixent's revenue after patent expiry.